Streetbeat News

Revenues

FHN

Analysts' ratings for First Horizon (NYSE:FHN) vary from bullish to bearish, with 8 analysts providing insights. The average 12-month price target is $18.06, reflecting a 1.4% increase from the previous target. Analysts' actions include maintaining, raising, and lowering ratings, with price targets ranging from $16.00 to $19.00. First Horizon's financial performance shows positive revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 12:00 pm

DCTH

Delcath Systems (NASDAQ:DCTH) has been analyzed by 4 financial analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target has increased to $21.75, with a high of $25.00 and a low of $18.00. Analysts have maintained or raised their ratings, reflecting positive market dynamics and company performance. Despite strong revenue growth, Delcath faces challenges in profitability and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

August 06, 2024 | 12:00 pm

MCRB

Seres Therapeutics has signed an agreement with Société Des Produits Nestlé to sell its VOWST business to Nestlé Health Science. Seres will receive upfront payments, milestone payments, and an equity investment, along with installment payments in 2025 and potential future payments based on VOWST net sales targets. Seres will provide transition and manufacturing support through 2025 and will share 50/50 in the profit and loss of the business through the end of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:58 am

HRMY

Harmony Biosciences has reiterated its 2024 net product revenue guidance of $700M - $720M, aligning with the estimated $710.288M. The company reported cash, cash equivalents, and investments of $434.1 million as of June 30, 2024, up from $425.6 million as of December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:57 am

SRE

Sempra (NYSE:SRE) reported Q2 2024 adjusted EPS of $0.89, missing the analyst estimate of $0.94. Sales were $3.011 billion, also missing the estimate of $3.404 billion and down 9.72% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:56 am

GBTG

Global Business Travel Group (GBTG) has reiterated its FY24 revenue guidance of $2.43B-$2.50B, raised its full-year 2024 Free Cash Flow guidance, and expects significant Adjusted EBITDA growth. The guidance does not include the impact of the CWT acquisition expected to close in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:56 am

BWAY

BrainsWay (NASDAQ:BWAY) reported Q2 earnings of $0.04 per share, a significant improvement from a loss of $(0.10) per share YoY. The company also reported sales of $10.01 million, beating the $9.25 million estimate and showing a 27.79% increase from $7.83 million YoY.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:51 am

ALIT

Alight expects its revenue for the second half of FY24 to be between $1.207 billion and $1.232 billion, with adjusted EPS ranging from $0.31 to $0.36. The company also projects BPaaS revenue of $265 to $275 million, adjusted EBITDA of $326 million to $351 million, and an adjusted EBITDA margin of 26.5% to 29.1%. Operating cash flow conversion is expected to be 55-65%.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:51 am

VMC

Vulcan Materials (VMC) has provided its financial outlook for 2024, expecting net earnings between $0.95 billion and $1.07 billion, and adjusted EBITDA between $2 billion and $2.15 billion. Despite weather disruptions affecting construction activity and operating efficiencies, the company anticipates continued improvement in aggregates cash gross profit per ton and a positive pricing environment.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:50 am

ENFN

Enfusion continues to expect FY24 GAAP revenues of $200M - $210M, aligning with the estimated $205.565M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:48 am